Cannabinoid signaling in glial cells in health and disease

Current Neuropharmacology

Volumn 2, Issue 1, 2004, Pages 115-124

  Witting, Anke ^a   Stella, Nephi ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Astrocytes; Cannabinoids; Endocannabinoids; Glial cells; Microglia; Oligodendrocytes

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIBIOTIC AGENT; ARACHIDONIC ACID; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; ENDOTHELIN 1; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN BASIC PROTEIN; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; REACTIVE OXYGEN METABOLITE;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; ASTROCYTE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CELL CULTURE; CELL MIGRATION; CELL TYPE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GAP JUNCTION; GLIA CELL; GLUCOSE METABOLISM; HOMEOSTASIS; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RAT; REVIEW; SIGNAL TRANSDUCTION;

EID: 3042615076     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476855     Document Type: Review

References (83)

1. Abood, M.E., Rizvi, G., Sallapudi, N. and McAllister, S.D. (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett., 309, 197-201.
2. Achiron, A., Miron, S., Lavie, V., Margalit, R. and Biegon, A. (2000) Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol., 102, 26-31.
3. Arevalo-Martin, A., Vela, J.M., Molina-Holgado, E., Borrell, J. and Guaza, C. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci., 23, 2511-2516.
4. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Huffman, J.W. and Layward, L. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 404, 84-87.
5. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T. and Di Marzo, V. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J., 15, 300-302.
6. Bar-Joseph, A., Berkovitch, Y., Adamchik, J. and Biegon, A. (1994) Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol., 23, 125-135.
7. Bass, R., Engelhard, D., Trembovler, V. and Shohami, E. (1996) A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J. Infect. Dis., 173, 735-738.
8. Baumann, N. and Pham-Dinh, D. (2001) Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev., 81, 871-927.
9. Belayev, L., Bar-Joseph, A., Adamchik, J. and Biegon, A. (1995) HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol. Chem. Neuropathol., 25, 19-33.
10. Belayev, L., Busto, R., Watson, B.D. and Ginsberg, M.D. (1995) Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study. Brain Res., 702, 266-270.
11. Belayev, L., Busto, R., Zhao, W. and Ginsberg, M.D. (1995) HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke, 26, 2313-2319.
12. Beltramo, M. and Piomelli, D. (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport, 11, 1231-1235.
13. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A. and Piomelli, D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094-1097.
14. Blazquez, C., Sanchez, C., Daza, A., Galve-Roperh, I. and Guzman, M. (1999) The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. J. Neurochem., 72, 1759-1768.
15. Bouaboula, M., Bourrie, B., Rinaldi-Carmona, M., Shire, D., Le Fur, G. and Casellas, P. (1995) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem., 270, 13973-13980.
16. Bouaboula, M., Poinot-Chazel, C., Bourrie, B., Canat, X., Calandra, B., Rinaldi-Carmona, M., Le Fur, G. and Casellas, P. (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J., 312 (Pt 2), 637-641.
17. Cabral, G.A., Harmon, K.N. and Carlisle, S.J. (2001) Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv. Exp. Med. Biol., 493, 207-214.
18. Cadas, H., Gaillet, S., Beltramo, M., Venance, L. and Piomelli, D. (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci., 16, 3934-3942.
19. Carlisle, S.J., Marciano-Cabral, F., Staab, A., Ludwick, C. and Cabral, G.A. (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol., 2, 69-82.
20. Chen, Y. and Swanson, R.A. (2003) Astrocytes and brain injury. J. Cereb. Blood Flow Metab, 23, 137-149.
21. Clifford, D.B. (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol., 13, 669-671.
22. Consroe, P., Musty, R., Rein, J., Tillery, W. and Pertwee, R. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol., 38, 44-48.
23. Croxford, J.L. and Miller, S.D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J. Clin. Invest., 111, 1231-1240.
24. Deutsch, D.G., Glaser, S.T., Howell, J.M., Kunz, J.S., Puffenbarger, R.A., Hillard, C.J. and Abumrad, N. (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem., 276, 6967-6973.
25. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C. and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
26. Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R. and Brotchie, J.M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J., 14, 1432-1438.
27. Esposito, G., Izzo, A.A., Di Rosa, M. and Iuvone, T. (2001) Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J. Neurochem., 78, 835-841.
28. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. and Leon, A. (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia, 41, 161-168.
29. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. and Guzman, M. (2002) Mechanism of Extracellular Signal-Regulated Kinase Activation by the CB(1) Cannabinoid Receptor. Mol. Pharmacol., 62, 1385-1392.
30. Galve-Roperh, I., Sanchez, C., Cortes, M.L., Gomez del Pulgar, T., Izquierdo, M. and Guzman, M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med., 6, 313-319.
31. Giaume, C., Tabernero, A. and Medina, J.M. (1997) Metabolic trafficking through astrocytic gap junctions. Glia, 21, 114-123.
32. Glaser, S.T., Abumrad, N.A., Fatade, F., Kaczocha, M., Studholme, K.M. and Deutsch, D.G. (2003) Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. USA, 100, 4269-4274.
33. Gomez del Pulgar, T., de Ceballos, M.L., Guzman, M. and Velasco, G. (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem., 277(39), 36527-33.
34. Gomez del Pulgar, T., Velasco, G. and Guzman, M. (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J., 347, 369-373.
35. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. and Guzman, M. (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J., 363, 183-188.
36. Grundy, R.I. (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert. Opin. Investig. Drugs, 11, 1365-1374.
37. Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agro, A. and Maccarrone, M. (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci., 22, 6900-6907.
38. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R. and Pertwee, R.G. (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev., 54, 161-202.
39. Jung, M., Calassi, R., Rinaldi-Carmona, M., Chardenot, P., Le Fur, G., Soubrie, P. and Oury-Donat, F. (1997) Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. J. Neurochem., 68, 402-409.
40. Kreutzberg, G.W. (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-318.
41. Leker, R.R., Shohami, E., Abramsky, O. and Ovadia, H. (1999) Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J. Neurol. Sci., 162, 114-119.
42. Louw, D.F., Yang, F.W. and Sutherland, G.R. (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res., 857, 183-187.
43. Lyman, W.D., Sonett, J.R., Brosnan, C.F., Elkin, R. and Bornstein, M.B. (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol., 23, 73-81.
44. Maccarrone, M., Attina, M., Cartoni, A., Bari, M. and Finazzi-Agro, A. (2001) Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J. Neurochem., 76, 594-601.
45. Maccarrone, M., Gubellini, P., Bari, M., Picconi, B., Battista, N., Centonze, D., Bernardi, G., Finazzi-Agro, A. and Calabresi, P. (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem., 85, 1018-1025.
46. Marinissen, M.J. and Gutkind, J.S. (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci., 22, 368-376.
47. Martyn, C.N., Illis, L.S. and Thom, J. (1995) Nabilone in the treatment of multiple sclerosis. Lancet, 345, 579.
48. Mittelbronn, M., Dietz, K., Schluesener, H.J. and Meyermann, R. (2001) Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. (Berl.), 101, 249-255.
49. Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Almazan, G., Molina-Holgado, F., Borrell, J. and Guaza, C. (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci., 22, 9742-9753.
50. Molina-Holgado, F., Lledo, A. and Guaza, C. (1997) Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport, 8, 1929-1933.
51. Molina-Holgado, F., Molina-Holgado, E. and Guaza, C. (1998) The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes - infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett., 433, 139-142.
52. Molina-Holgado, F., Molina-Holgado, E., Guaza, C. and Rothwell, N.J. (2002) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res., 67, 829-836.
53. Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K. and Greenberg, D.A. (1999) Cannabinoids and neuro-protection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci., 19, 2987-2995.
54. Parmentier-Batteur, S., Jin, K., Mao, X.O., Xie, L. and Greenberg, D.A. (2002) Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice. J. Neurosci., 22, 9771-9775.
55. Petro, D.J. and Ellenberger, C. Jr. (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J. Clin. Pharmacol., 21, 413S-416S.
56. Piomelli, D., Beltramo, M., Giuffrida, A. and Stella, N. (1998) Endogenous cannabinoid signaling. Neurobiol. Dis., 5, 462-473.
57. Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S.Y., Goutopoulos, A., Xie, X.Q. and Makriyannis, A. (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA, 96, 5802-5807.
58. Puffenbarger, R.A., Boothe, A.C. and Cabral, G.A. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia, 29, 58-69.
59. Rezaie, P. and Male, D. (1999) Colonisation of the developing human brain and spinal cord by microglia: a review. Microsc. Res. Tech., 45, 359-382.
60. Romero, J., Hillard, C.J., Calero, M. and Rabano, A. (2002) Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res. Mol. Brain Res., 100, 85-93.
61. Sagan, S., Venance, L., Torrens, Y., Cordier, J., Glowinski, J. and Giaume, C. (1999) Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci., 11, 691-699.
62. Salio, C., Doly, S., Fischer, J., Franzoni, M.F. and Conrath, M. (2002) Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci. Lett., 329, 13-16.
63. Sanchez, C., de Ceballos, M.L., Gomez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Huffman, J.W., Ramon, Y.C. and Guzman, M. (2001) Inhibition of glioma growth in vivo by selective activation of the cb(2) cannabinoid receptor. Cancer Res., 61, 5784-5789.
64. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. and Guzman, M. (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett., 436, 6-10.
65. Sanchez, C., Galve-Roperh, I., Rueda, D. and Guzman, M. (1998) Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol., 54, 834-843.
66. Sanchez, C., Rueda, D., Segui, B., Galve-Roperh, I., Levade, T. and Guzman, M. (2001) The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol., 59, 955-959.
67. Sanchez, C., Velasco, G. and Guzman, M. (1997) Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Res., 767, 64-71.
68. Shivachar, A.C., Martin, B.R. and Ellis, E.F. (1996) Anandandamide and Delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [n-(piperidin-lyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4Methyl-1H-pyrazole-3-carboximide Hydrochloride]. Biochem. Pharmacol., 51, 669-676.
69. Shohami, E., Gallily, R., Mechoulam, R., Bass, R. and Ben Hur, T. (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol., 72, 169-177.
70. Sinha, D., Bonner, T.I., Bhat, N.R. and Matsuda, L.A. (1998) Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J. Neuroimmunol., 82, 13-21.
71. Stefano, G.B., Liu, Y. and Goligorsky, M.S. (1996) Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem., 271, 19238-19242.
72. Stella, N., Schweitzer, P. and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773-778.
73. Streit, W.J. (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia, 40, 133-139.
74. Suarez, I., Bodega, G., Fernandez-Ruiz, J.J., Ramos, J.A., Rubio, M. and Fernandez, B. (2002) Reduced Glial Fibrillary Acidic Protein and Glutamine Synthetase Expression in Astrocytes and Bergmann Glial Cells in the Rat Cerebellum Caused by Delta(9)-Tetrahydrocannabinol Administration during Development. Dev. Neurosci., 24, 300-312.
75. Venance, L., Cordier, J., Monge, M., Zalc, B., Glowinski, J. and Giaume, C. (1995) Homotypic and heterotypic coupling mediated by gap junctions during glial cell differentiation in vitro. Eur. J. Neurosci., 7, 451-461.
76. Venance, L., Piomelli, D., Glowinski, J. and Giaume, C. (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature, 376, 590-594.
77. Vered, M., Bar-Joseph, A., Belayev, L., Berkovich, Y. and Biegon, A. (1994) Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid. Acta Neurochir. Suppl (Wien.), 60, 335-337.
78. Voutsinos-Porche, B., Bonvento, G., Tanaka, K., Steiner, P., Welker, E., Chatton, J.Y., Magistretti, P.J. and Pellerin, L. (2003) Glial glutamate transporters mediate a functional metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. Neuron, 37, 275-286.
79. Waksman, Y., Olson, J.M., Carlisle, S.J. and Cabral, G.A. (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther., 288, 1357-1366.
80. Walter, L., Franklin, A., Witting, A., Moller, T. and Stella, N. (2002) Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem., 277, 20869-20876.
81. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K. and Stella, N. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 23, 1398-1405.
82. Walter, L. and Stella, N. (2003) Endothelin-1 increases 2-arachidonyl glycerol (2-AG) production in astrocytes. Glia., 44, 85-90.
83. Wirguin, I., Mechoulam, R., Breuer, A., Schezen, E., Weidenfeld, J. and Brenner, T. (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology, 28, 209-214.